P/B
0,3
Onconetix
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
$4.5M
Market Cap • 9/25/2026
2018
(8 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
22,8
EPS
248,1
Market Cap
Market Cap
4,5M
EV
-1,2M
EV/Revenue
-1,9
EV/EBITDA
0,1
EV/EBIT
0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-103,1%
Total Yield
-103,1%
Payout
0%
Retained Earnings
-138,3M
Profitability
Gross Margin
80,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
11,7%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,4%
% Goodwill
58,6%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
54,4%
CAGR Net Income 5Y
40,6%
CAGR OCF 5Y
56%
Leverage
N.D./EBITDA
0,4
Debt/Equity
0%
Current Ratio
2,2
Quick Ratio
2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!